ClinicalTrials.gg

Program

SAL-0951

A development code. Also written as “SAL-0951 tablets”, “SAL-0951 tablets 4mg” and “SAL-0951 tablets 5mg”.

Its studies are mostly in Anemia, led by Shenzhen Salubris Pharmaceuticals.

Furthest: phase 3, since Aug 23, 20234 company-led studies, 1 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Shenzhen Salubris Pharmaceuticals41 open or runningphase 3since Aug 23, 2023Aug 23, 2023none ahead

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Aug 23, 2023First study: phase 3 study in Renal Anemia in Non-dialysis Chronic Kidney DiseaseFirst studyNCT06016036 · 156 enrolled · China
  2. Dec 2, 20242 phase 3 studies in AnemiaNCT06720233, NCT06720025
  3. Dec 4, 2024Phase 2 study in AnemiaNCT06737081 · 60 planned · China

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 4 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06737081Anemia · China2RecruitingDec 31, 202560
NCT06720233Anemia · China3CompletedOct 18, 202437
NCT06720025Anemia · China3CompletedJun 17, 2024100
NCT06016036Renal Anemia in Non-dialysis Chronic Kidney Disease · China3CompletedOct 8, 2021156

How it is read

Names in the registry

  • “SAL-0951 tablets”, 2 entries
  • “SAL-0951 tablets 4mg”, 1 entry
  • “SAL-0951 tablets 5mg”, 1 entry
  • “SAL-0951”, 1 entry

Codes read as this program: SAL0951.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.